427 related articles for article (PubMed ID: 22772081)
1. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.
Shakhova O; Zingg D; Schaefer SM; Hari L; Civenni G; Blunschi J; Claudinot S; Okoniewski M; Beermann F; Mihic-Probst D; Moch H; Wegner M; Dummer R; Barrandon Y; Cinelli P; Sommer L
Nat Cell Biol; 2012 Aug; 14(8):882-90. PubMed ID: 22772081
[TBL] [Abstract][Full Text] [Related]
2. Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.
Su Z; Zheng X; Zhang X; Wang Y; Zhu S; Lu F; Qu J; Hou L
J Dermatol Sci; 2017 Mar; 85(3):216-225. PubMed ID: 27955842
[TBL] [Abstract][Full Text] [Related]
3. Expression of SOX10, ABCB5 and CD271 in melanocytic lesions and correlation with survival data of patients with melanoma.
Gambichler T; Petig AL; Stockfleth E; Stücker M
Clin Exp Dermatol; 2016 Oct; 41(7):709-16. PubMed ID: 27663144
[TBL] [Abstract][Full Text] [Related]
4. SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis.
Cronin JC; Watkins-Chow DE; Incao A; Hasskamp JH; Schönewolf N; Aoude LG; Hayward NK; Bastian BC; Dummer R; Loftus SK; Pavan WJ
Cancer Res; 2013 Sep; 73(18):5709-18. PubMed ID: 23913827
[TBL] [Abstract][Full Text] [Related]
5. SOX10 expression in malignant melanoma, carcinoma, and normal tissues.
Mohamed A; Gonzalez RS; Lawson D; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):506-10. PubMed ID: 23197006
[TBL] [Abstract][Full Text] [Related]
6. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.
Rosenbaum SR; Tiago M; Caksa S; Capparelli C; Purwin TJ; Kumar G; Glasheen M; Pomante D; Kotas D; Chervoneva I; Aplin AE
Cell Rep; 2021 Dec; 37(10):110085. PubMed ID: 34879275
[TBL] [Abstract][Full Text] [Related]
7. The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion.
Graf SA; Heppt MV; Wessely A; Krebs S; Kammerbauer C; Hornig E; Strieder A; Blum H; Bosserhoff AK; Berking C
Pigment Cell Melanoma Res; 2019 May; 32(3):424-434. PubMed ID: 30506895
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma.
Shakhova O; Cheng P; Mishra PJ; Zingg D; Schaefer SM; Debbache J; Häusel J; Matter C; Guo T; Davis S; Meltzer P; Mihic-Probst D; Moch H; Wegner M; Merlino G; Levesque MP; Dummer R; Santoro R; Cinelli P; Sommer L
PLoS Genet; 2015 Jan; 11(1):e1004877. PubMed ID: 25629959
[TBL] [Abstract][Full Text] [Related]
9. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
[TBL] [Abstract][Full Text] [Related]
10. Functional in vivo characterization of sox10 enhancers in neural crest and melanoma development.
Cunningham RL; Kramer ET; DeGeorgia SK; Godoy PM; Zarov AP; Seneviratne S; Grigura V; Kaufman CK
Commun Biol; 2021 Jun; 4(1):695. PubMed ID: 34099848
[TBL] [Abstract][Full Text] [Related]
11. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes.
Seong I; Min HJ; Lee JH; Yeo CY; Kang DM; Oh ES; Hwang ES; Kim J
PLoS One; 2012; 7(2):e31477. PubMed ID: 22363655
[TBL] [Abstract][Full Text] [Related]
12. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.
Yokoyama S; Takahashi A; Kikuchi R; Nishibu S; Lo JA; Hejna M; Moon WM; Kato S; Zhou Y; Hodi FS; Song JS; Sakurai H; Fisher DE; Hayakawa Y
Cancer Res; 2021 Dec; 81(24):6131-6141. PubMed ID: 34728538
[TBL] [Abstract][Full Text] [Related]
13. Kinesin family member 20A is a novel melanoma-associated antigen.
Yamashita J; Fukushima S; Jinnin M; Honda N; Makino K; Sakai K; Masuguchi S; Inoue Y; Ihn H
Acta Derm Venereol; 2012 Nov; 92(6):593-7. PubMed ID: 22854760
[TBL] [Abstract][Full Text] [Related]
14. Distant regulatory elements in a Sox10-beta GEO BAC transgene are required for expression of Sox10 in the enteric nervous system and other neural crest-derived tissues.
Deal KK; Cantrell VA; Chandler RL; Saunders TL; Mortlock DP; Southard-Smith EM
Dev Dyn; 2006 May; 235(5):1413-32. PubMed ID: 16586440
[TBL] [Abstract][Full Text] [Related]
15. A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas.
Tacha D; Qi W; Ra S; Bremer R; Yu C; Chu J; Hoang L; Robbins B
Arch Pathol Lab Med; 2015 Apr; 139(4):530-6. PubMed ID: 25436903
[TBL] [Abstract][Full Text] [Related]
16. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.
Capparelli C; Purwin TJ; Glasheen M; Caksa S; Tiago M; Wilski N; Pomante D; Rosenbaum S; Nguyen MQ; Cai W; Franco-Barraza J; Zheng R; Kumar G; Chervoneva I; Shimada A; Rebecca VW; Snook AE; Hookim K; Xu X; Cukierman E; Herlyn M; Aplin AE
Nat Commun; 2022 Mar; 13(1):1381. PubMed ID: 35296667
[TBL] [Abstract][Full Text] [Related]
17. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
18. SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Yang X; Liang R; Liu C; Liu JA; Cheung MPL; Liu X; Man OY; Guan XY; Lung HL; Cheung M
J Exp Clin Cancer Res; 2019 Jan; 38(1):17. PubMed ID: 30642390
[TBL] [Abstract][Full Text] [Related]
19. c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi.
Ohashi A; Funasaka Y; Ueda M; Ichihashi M
Melanoma Res; 1996 Feb; 6(1):25-30. PubMed ID: 8640066
[TBL] [Abstract][Full Text] [Related]
20. PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas).
Medic S; Ziman M
PLoS One; 2010 Apr; 5(4):e9977. PubMed ID: 20421967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
